Global Osteoporosis Drugs Market - 2023-2030

Market Overview

The Global Osteoporosis Drugs Market reached US$ 14,066.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 19,336.6 million by 2030. The global osteoporosis drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).

The global market for osteoporosis medications is expanding as a result of factors including the increasing prevalence of post menstruation osteoporosis, the growing size of the therapeutic pipeline, expenditures by biopharmaceutical companies and the creation of more sophisticated diagnostics for early detection.

The global osteoporosis drugs market is also expanding owing to the the increasing research studies for osteoporosis drugs, rising regulatory approvals for novel products, rising geriatric population, new novel technologically advanced therapies.

Market Dynamics

The Growing Investments in Research and Development by Biotechnology and Pharmaceutical Companies Drive the Growth of the Osteoporosis Drugs Market

The growing number of research studies on osteoporosis medicines, the growing investments by major biopharmaceutical companies, an increase in the population of older people, and new, innovative, technologically sophisticated therapies are all contributing to the growth of the global market for osteoporosis drugs.

For instance in April 2023, Van Andel Research Institute published a report which reported that the scientists have identified a crucial factor that contributes to decreased bone density; this finding may result in more effective medicines with fewer adverse effects for women with osteoporosis.

According to the research, mice's bone mass is preserved when an epigenetic modulator called KDM5C is lost. KDM5C functions by changing epigenetic "marks," which are similar to "on" and "off" switches that make sure the DNA instructions are used at the appropriate time and location.

Growing Clinical Trials and Rising Geriatric Population Creates Lucrative Opportunities for Manufacturers

Due to key players' significant investments for clinical trials in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for osteoporosis treatment is geriatric population. According to the 2021 American Community Survey, 16.8% of the country's population, or 55,892,014 persons, was 65 years of age or older.

Furthermore, researchers are conducting various clinical trials for osteoporosis treatment. In October 2022, data obtained from the Phase 3 Abaloparatide for the treating men with Osteoporosis clinical trial (NCT03512262) comparing abaloparatide to a placebo has been published in the Journal of Bone and Mineral Research, according to a statement from Radius Health, Inc.

A human parathyroid hormone-linked peptide analog called TYMLOS (abaloparatide) is already approved for the management of postmenopausal women with osteoporosis who are at a high risk of fracture.

A Low Rate of Treatment With Bone-Directed Medications will Hamper the Growth of the Market

The global marketplace for osteoporosis drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low rate of treatment with bone-directed medicines for osteoporosis disease.

Less than one in ten economically insured patients in the United States who got a hip fracture, one of the highly serious adverse effects of osteoporosis, obtained any osteoporosis medical treatment during the first two calendar quarters of their fracture, according to a study whose results were presented at the Endocrine Society's annual meeting, ENDO 2021. These factors prevent market expansion over the expected time period.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global osteoporosis drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global osteoporosis drugs market growth over the forecast period.

Segment Analysis

The global osteoporosis drugs market is segmented based on drug class, product type, distribution channel and region.

Hospital Pharmacy from Distribution Channel Segment Accounts for 42.1% of Market Share Owing to Rising Hospital Admissions

The ultimate objective of hospital pharmacy is to maintain and enhance patient drug administration at all times. Hospital pharmacists' primary duty is to regulate the use of medications in hospitals and other healthcare facilities. Through the prescription, purchasing, distribution, monitoring, and review of drugs, one of the objectives is to improve patient outcomes.

Hospital pharmacies will see an increase in demand benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use and making sure the container can be read and opened with ease. identifying potential health issues unrelated to osteoporosis. Hence above mentioned factors prove that hospital pharmacy will be the largest market shareholder.

Geographical Analysis

North America Accounted for Approximately 38.7% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for osteoporosis drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of osteoporosis drugs, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of osteoporosis drugs. Rising new product launches for using in men and women with osteoporosis will drive the market growth.

Growth is also fueled by the rising technological advancements, regulatory approvals and novel product launches. Reseaerchers are becoming more aware of various kinds of diagnostics or treatment approaches for osteoporosis, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the osteoporosis drugs market include: F. Hoffmann-La Roche, Novartis AG, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Amgen Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd. and Radius Health Inc. among others.

Why Purchase the Report?

• To visualize the global osteoporosis drugs market segmentation based on drug class, product type, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of osteoporosis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global osteoporosis drugs market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies